Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,380.63 Bn | 66,380.34 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,910.39 Bn | 1,910.33 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.95 Bn | 466.16 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.92 Bn | 61.16 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.58 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 31.42% |
| 10 | Lineage Cell Therapeutics | 248.70 Mn | 185.99 Mn | 1.73 Mn | 10.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.63% |
| Dec 31, 2025 | 12.05% |
| Sep 30, 2025 | 15.09% |
| Jun 30, 2025 | 8.12% |
| Mar 31, 2025 | -30.61% |
| Dec 31, 2024 | -4.66% |
| Sep 30, 2024 | -5.22% |
| Jun 30, 2024 | 1.96% |
| Mar 31, 2024 | 7.83% |
| Dec 31, 2023 | -2.55% |
| Sep 30, 2023 | -2.05% |
| Jun 30, 2023 | -15.61% |
| Mar 31, 2023 | -31.28% |
| Dec 31, 2022 | -12.63% |
| Sep 30, 2022 | 8.44% |
| Jun 30, 2022 | 10.13% |
| Mar 31, 2022 | 62.68% |
| Dec 31, 2021 | 1.36% |
| Sep 30, 2021 | 13.19% |
| Jun 30, 2021 | 9.33% |